Hansoh Pharmaceutical Group Company Limited (HK:3692)
:3692
Want to see HK:3692 full AI Analyst Report?
3692 Stock Chart & Stats
HK$39.76
HK$0.26(1.60%)
At close: 4:00 PM EST
HK$39.76
HK$0.26(1.60%)
Day’s Range― - ―
52-Week RangeHK$24.45 - HK$44.22
Previous CloseN/A
Volume4.63M
Average Volume (3M)9.67M
Market Cap
HK$203.76B
Enterprise ValueHK$173.65B
Total Cash (Recent Filing)HK$31.58B
Total Debt (Recent Filing)HK$105.14M
Price to Earnings (P/E)34.9
Beta0.54
Next Earnings
Aug 20, 2026EPS Estimate
0.56Next Dividend Ex-DateN/A
Dividend Yield0.97%
Share Statistics
EPS (TTM)0.93
Shares Outstanding6,064,150,000
10 Day Avg. Volume6,926,281
30 Day Avg. Volume9,666,344
Financial Highlights & Ratios
PEG Ratio1.36
Price to Book (P/B)5.48
Price to Sales (P/S)12.90
P/FCF Ratio31.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$46.44Price Target Upside16.79% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)0.99
Revenue Forecast (FY)HK$16.93B
Bulls Say, Bears Say
Bulls Say
High ProfitabilityExceptionally high gross and net margins indicate strong pricing power and efficient manufacturing for branded drugs. Durable profitability supports sustained R&D and commercialization spending, underpins healthy ROE, and provides resilience to cyclical downturns in the medium term.
Conservative Balance SheetExtremely low leverage gives the company financial flexibility to fund pipeline investments, M&A, or weather reimbursement shifts without material refinancing risk. Low interest burden supports margin stability and preserves capacity for strategic capital allocation.
Strong Cash GenerationOperating cash flow comfortably above net income and robust free cash flow indicate high earnings quality and internal funding for R&D, commercialization, and shareholder returns. Improved cash conversion versus prior year strengthens durable liquidity and reinvestment capacity.
Bears Say
Margin VariabilityYear-to-year swings in operating margins suggest recurring risks from product mix, pricing pressure, or cost timing. Such variability makes long-term earnings less predictable, complicates budgeting for R&D and commercialization, and can amplify performance risk during policy shifts.
Cash Conversion VolatilityPeriods where cash flow lagged earnings show that profits do not always convert reliably to cash, exposing the company to working-capital and timing risks. Recurring cash conversion swings can limit sustained investment capacity and increase reliance on external financing in weak years.
Historical Leverage SwingsPrior episodes of materially higher leverage indicate management has employed debt cyclically. While current leverage is low, historical swings suggest potential for re-leveraging under stress or opportunistic deals, which could raise financial risk if profitability or cash flow weaken.
Hansoh Pharmaceutical Group Company Limited News
3692 FAQ
What was Hansoh Pharmaceutical Group Company Limited’s price range in the past 12 months?
Hansoh Pharmaceutical Group Company Limited lowest stock price was HK$24.45 and its highest was HK$44.22 in the past 12 months.
What is Hansoh Pharmaceutical Group Company Limited’s market cap?
Hansoh Pharmaceutical Group Company Limited’s market cap is HK$203.76B.
When is Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date?
Hansoh Pharmaceutical Group Company Limited’s upcoming earnings report date is Aug 20, 2026 which is in 91 days.
How were Hansoh Pharmaceutical Group Company Limited’s earnings last quarter?
Hansoh Pharmaceutical Group Company Limited released its earnings results on Mar 29, 2026. The company reported HK$0.461 earnings per share for the quarter, beating the consensus estimate of HK$0.392 by HK$0.069.
Is Hansoh Pharmaceutical Group Company Limited overvalued?
According to Wall Street analysts Hansoh Pharmaceutical Group Company Limited’s price is currently Undervalued.
Does Hansoh Pharmaceutical Group Company Limited pay dividends?
Hansoh Pharmaceutical Group Company Limited pays a Quarterly dividend of HK$0.232 which represents an annual dividend yield of 0.97%. See more information on Hansoh Pharmaceutical Group Company Limited dividends here
What is Hansoh Pharmaceutical Group Company Limited’s EPS estimate?
Hansoh Pharmaceutical Group Company Limited’s EPS estimate is 0.56.
How many shares outstanding does Hansoh Pharmaceutical Group Company Limited have?
Hansoh Pharmaceutical Group Company Limited has 6,064,150,000 shares outstanding.
What happened to Hansoh Pharmaceutical Group Company Limited’s price movement after its last earnings report?
Hansoh Pharmaceutical Group Company Limited reported an EPS of HK$0.461 in its last earnings report, beating expectations of HK$0.392. Following the earnings report the stock price went down -0.648%.
Which hedge fund is a major shareholder of Hansoh Pharmaceutical Group Company Limited?
Currently, no hedge funds are holding shares in HK:3692
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hansoh Pharmaceutical Group Company Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
67.01%
12-Months-Change
Fundamentals
Return on Equity
16.59%
Trailing 12-Months
Asset Growth
31.91%
Trailing 12-Months
Company Description
Hansoh Pharmaceutical Group Company Limited
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including central nervous system diseases, oncology, anti-infectives, and metabolic diseases. Its principal products include Mailingda, a drug for the treatment of chronic myelogenous leukemia; and Ameile, Hansoh Xinfu, Pulaile, Zefei, Xinwei, Xinmei, Xintai, Tanneng, Oulanning, Ameining, Zetan, Hengjie, Hengsen, Fulaimei, Fulaidi, and Ruibote drugs. The company serves pharmaceutical product distributors. It has a strategic collaboration with Scynexis, Inc. to develop and commercialize ibrexafungerp for treatment of vaginal yeast infections; and strategic collaboration with Keros to develop, manufacture, and commercialize KER-050 for treatment of cytopenias, anemia, and thrombocytopenia. The company also has a collaboration with Olix Pharmaceuticals for development of drug candidates for cardiovascular, metabolic, and other diseases associated with the liver; and strategic collaboration with Silence Therapeutics plc to develop siRNAs for three targets leveraging Silence's mRNAi GOLD platform. The company was founded in 1995 and is headquartered in Lianyungang, the People's Republic of China. Hansoh Pharmaceutical Group Company Limited is a subsidiary of Stellar Infinity Company Ltd.
3692 Stock 12 Month Forecast
Average Price Target
HK$46.44
▲(16.79% Upside)
Technical Analysis
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
Grand Pharmaceutical Group Limited
―
Options Prices
Currently, No data available
---